Moreover, the AASLD is at the forefront of establishing evidence-based guidelines for the diagnosis and management of a broad range of liver conditions.2 Despite the enormous scientific and medical progress in the management of liver disease, a substantial gap remains between the recommended standards of hepatology care and the care actually delivered to patients within our communities.
Consequently, we call for greater investment in research focused on the development and implementation of innovative Small molecule library solubility dmso approaches to the systematic delivery of high-quality hepatology care to all Americans. As reported in a previous AASLD Public Policy Corner,3 the final, least tested, and most important steps for effectively applying scientific
and medical discoveries to improve health are the application of evidence-based guidelines to health practice [termed phase 3 translational (T3) research] and the evaluation of real-world outcomes of specific health care interventions [termed phase 4 translational (T4) research].3 Although hepatologists have contributed to a deep understanding of disease pathophysiology [phase 0 translational research and phase 1 translational (T1) research] and the optimal management of individual patients with liver disease [phase 2 translational (T2) research], the development Everolimus cost and implementation of health care delivery strategies (T3 research) and the analysis of their effects on clinical outcomes (T4 research) have been limited. The National Institute of Diabetes and Digestive and Kidney Diseases
(NIDDK) has instituted the Action Plan for Liver Disease Research. This plan includes the following specific goals, which will require T3 and T4 research to be successfully achieved4: Improve the success rate of hepatitis C therapy. Develop effective therapies that can be used in both alcoholic and nonalcoholic fatty liver disease. ADAMTS5 Develop regimens of antiviral therapy that are effective in the long-term management of hepatitis B. Develop sensitive and specific means of screening individuals at high risk for early hepatocellular carcinoma. Improve the safety and define the optimal use of living donor liver transplantation. Decrease the mortality rate from liver disease. This NIDDK framework is committed to advancing prevention, effective therapy, screening, safety, optimization of limited resources (e.g., liver transplantation), standardization of care, and decreased mortality from liver disease within 10 years.